{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-046455","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.611499+00:00","generated_at":"2026-06-17T00:49:57.081737+00:00","sec_items":["2.02","8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immuneering reports positive early Phase 1 data for IMM-1-104; accelerates RP2D timeline to early 2024","bullets":["IMM-1-104 shows >90% pERK inhibition at 160mg QD; PK Cmax >2,000 ng/mL; half-life ~2 hours.","No dose-limiting toxicities or SAEs; only Grade 1 drug-related AEs; well tolerated across four patients.","RP2D announcement accelerated to early 2024 from prior guidance of mid-2024.","Preliminary cash $91.5M at March 31, 2023; expected funding into Q4 2024.","Data from patients with pancreatic and colorectal cancer with KRAS G12D, G12V, NRAS Q61L, Q61K."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-046455","json":"https://secwatch.observer/filing/0001104659-23-046455.json","markdown":"https://secwatch.observer/filing/0001104659-23-046455.md","text":"https://secwatch.observer/filing/0001104659-23-046455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000110465923046455/0001104659-23-046455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000110465923046455/tm2312981d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:49:57.081737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}